91桃色

Fibrous dysplasia; Skeletal disorder; Bone deformity; Monostotic; Polyostotic; GNAS mutation; Orthopedic management; Fibro-osseous lesion; Bone pain; Bone remodeling

Introduction

Fibrous dysplasia is a skeletal anomaly first described in the early 20th century, involving the abnormal development of fibrous tissue within the bone. This condition disrupts the normal architecture and strength of the skeletal system, resulting in a spectrum of clinical problems ranging from asymptomatic lesions to severe deformities and functional limitations. The disease can be isolated to a single bone (monostotic) or affect multiple bones (polyostotic), sometimes in conjunction with endocrine abnormalities and skin pigmentation, as seen in McCune-Albright syndrome. Despite its benign histological nature, FD can be progressive and debilitating. Given its rarity and heterogeneous presentation, fibrous dysplasia remains a diagnostic and therapeutic challenge for clinicians across multiple specialties, including orthopedics, radiology, pathology, and endocrinology [1].

Description

Fibrous dysplasia results from postzygotic activating mutations in the GNAS gene, which encodes the alpha subunit of the stimulatory G protein (Gsα). This mutation leads to constitutive activation of adenylate cyclase and increased cyclic AMP (cAMP) levels, affecting the differentiation of osteogenic cells [2]. As a consequence, normal lamellar bone is replaced with structurally unsound woven bone embedded in fibrous stroma, compromising mechanical integrity and predisposing to deformities and fractures [3]. The monostotic form, accounting for approximately 70-80% of cases, typically affects the ribs, femur, tibia, or craniofacial bones and often presents during adolescence or early adulthood. The polyostotic variant involves multiple skeletal regions and can be associated with skin pigmentation (café-au-lait spots) and endocrinopathies such as precocious puberty, hyperthyroidism, or growth hormone excess. This syndromic manifestation is termed McCune-Albright syndrome [4].

Patients may present with localized pain, swelling, deformity, pathological fractures, or incidentally discovered lesions on radiographs. Craniofacial involvement can result in facial asymmetry, visual or auditory disturbances, and dental anomalies. Radiologically, FD lesions show a characteristic "ground-glass" appearance due to the fine trabeculation of dysplastic bone [5]. CT and MRI provide further details on lesion extent, cortical integrity, and potential complications, while bone scintigraphy may be used to assess the full skeletal burden in polyostotic cases. Histologically, fibrous dysplasia is identified by irregular trabeculae of woven bone lacking osteoblastic rimming, embedded in a fibrous stroma. While biopsy is not always necessary for typical cases, it can be useful to exclude other fibro-osseous or neoplastic conditions when clinical or radiologic ambiguity exists [6].

Discussion

The management of fibrous dysplasia is highly individualized, given the variable clinical course and severity. Asymptomatic patients with stable lesions may only require periodic observation and radiographic follow-up. Pain management is typically conservative, involving NSAIDs, while bisphosphonates such as pamidronate have been employed to reduce bone turnover and alleviate pain, though their long-term efficacy and impact on disease progression remain under investigation [7]. Surgical intervention is considered in cases of significant deformity, pathological fractures, or functional impairment. Procedures may include curettage with bone grafting, corrective osteotomies, internal fixation, or in severe cases, joint replacement. However, surgical outcomes can be unpredictable due to poor bone quality and high recurrence rates of dysplastic lesions. In craniofacial FD, surgery aims to correct disfigurement and alleviate compression of vital structures, often necessitating a staged, multidisciplinary approach involving maxillofacial, ENT, and neurosurgical teams. One of the principal challenges in managing FD lies in its unpredictable progression. While some lesions stabilize after adolescence, others continue to expand and cause complications well into adulthood. Additionally, the risk of malignant transformation, although rare (<1%), warrants long-term monitoring, especially in previously irradiated lesions [8].

Recent research into the molecular underpinnings of fibrous dysplasia has opened potential avenues for targeted therapy. Inhibitors of the cAMP pathway, monoclonal antibodies, and gene editing strategies represent future possibilities. Nonetheless, these remain largely experimental and are not yet part of standard care [9]. Genetic counseling may be appropriate in syndromic or early-onset cases to inform families about the nature of the condition and its implications. Effective management of fibrous dysplasia necessitates a collaborative approach. Orthopedic surgeons, endocrinologists, radiologists, and pain specialists must coordinate care to address the diverse manifestations of the disease. Patient education is also critical, as individuals with FD must often navigate a lifelong course with varying degrees of physical and psychological impact [10].

Conclusion

Fibrous dysplasia, while histologically benign, presents a host of clinical challenges due to its unpredictable course, variable manifestations, and complex management needs. From initial diagnosis through long-term monitoring and intervention, a patient-centered, multidisciplinary strategy is essential. As our understanding of the molecular basis of FD continues to evolve, there is hope for more precise and effective therapies in the future. Until then, individualized care plans, careful surgical consideration, and continuous research remain the cornerstones of managing this enigmatic bone disorder.

References

1. Ingadottir AR, Bjorgvinsdottir EB, Beck A, Baldwin C, Weekes C, et al. (2020) . Clin Nutr 39: 1085-1091.

 , ,

2. Ogan N, Yıldırım F, Süzen B, Baha A, Akpınar EE, et al. (2020) . Turkish Thorac J 21: 49-53.

   

3. Maia I, Peleteiro B, Xará S, Amaral TF (2017) . J Am Coll Nutr 36: 137-147.

, ,

4. Law S, Kumar P, Woods S, Sriram KB (2016) . Hosp Pract (1995) 44: 207-212.

, ,

5. Vermeeren MA, Schols AM, Wouters EF (1997) . Eur Respir J 10: 2264-2269.

, ,

6. van Bokhorst-de, Guaitoli PR, Jansma EP, De-Vet HCW (2014) . Clin Nutr 33: 39-58.

, ,

7. Kovelis D, Segretti N, Probst V, Lareau S, Brunetto A, et al. (2008) . J Bras Pneumol 34: 1008-1018.

              , ,

8. Fischer M, JeVenn A, Hipskind P (2015) . Nutr Clin Pract 30: 239-248.

, ,

9. Landis J, Koch GG (1977) . Biometrics 33: 159-174.

, ,

10. Neelemaat F, Meijers J, Kruizenga H, Ballegooijen HV, van Bokhorst-de van der Schueren M, et al. (2011)  . J Clin Nurs 20: 2144-2152.

, ,